Background. To overcome challenges with traditional response assessment in anti-angiogenic agents, the current study uses T1 subtraction maps to quantify volumetric radiographic response in monotherapy with cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 (VEGFR2), hepatocyte growth factor receptor (MET), and AXL, in an open-label, phase II trial in patients with recurrent glioblastoma (GBM) (NCT00704288). Methods. A total of 108 patients with adequate imaging data and confirmed recurrent GBM were included in this retrospective study from a phase II multicenter trial of cabozantinib monotherapy (XL184-201) at either 100 mg (N = 87) or 140 mg (N = 21) per day. Contrast enhanced T1-weighted digital subtraction maps were used to define volume of contrast-enhancing tumor at baseline and subsequent follow-up time points. Volumetric radiographic response (>65% reduction in contrast-enhancing tumor volume from pretreatment baseline tumor volume sustained for more than 4 wk) was tested as an independent predictor of overall survival (OS). Results. Volumetric response rate for all therapeutic doses was 38.9% (41.4% and 28.6% for 100 mg and 140 mg doses, respectively). A log-linear association between baseline tumor volume and OS (P = 0.0006) and a linear correlation between initial change in tumor volume and OS (P = 0.0256) were observed. A significant difference in OS was observed between responders (median OS = 20.6 mo) and nonresponders (median OS = 8.0 mo) (hazard
ratio [HR] = 0.3050, P < 0.0001). Multivariable analyses showed that continuous measures of baseline tumor volume (HR = 1.0233, P < 0.0001) and volumetric response (HR = 0.2240, P < 0.0001) were independent predictors of OS. Conclusions. T1 subtraction maps provide value in determining response in recurrent GBM treated with cabozantinib and correlated with survival benefit.
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Importance of the study GBM is the most common malignant brain tumor in adults, and treatment options for patients with recurrent GBM are significantly limited. Cabozantinib is an oral inhibitor of tyrosine kinases, including VEGFR2, MET, and AXL, which are implicated in the pathophysiology of GBM. Previous studies examining radiographic response in anti-VEGF therapies have been challenging due to reduction in vascular permeability; however, T1 subtraction maps may overcome these challenges and allow for more accurate estimates of tumor burden. The current study demonstrates that patients with recurrent GBM who exhibit a significant and sustained reduction in contrast-enhancing tumor volume on T1 subtraction maps following treatment with cabozantinib exhibit a significant survival advantage. This suggests that T1 subtraction may be a better way of estimating tumor burden and that early changes may be a surrogate for clinical activity of cabozantinib.
Glioblastoma (GBM) is the most common malignant brain tumor in adults and accounts for more than 54% of all gliomas and 45% of all malignant primary brain and CNS tumors. 1 Median survival for non-elderly patients with GBM is only around 14 months, 2 with fewer than 10% of patients surviving beyond 5 years following initial diagnosis. 3 Standard of care for newly diagnosed GBM patients includes maximum surgical resection followed by radiotherapy plus concomitant temozolomide 2 until tumor recurrence or relapse. Upon recurrence, however, very few effective therapeutic options exist. Thus, there continues to be an unmet need for drug development in the setting of recurrent GBM.
GBM is a highly vascularized tumor, which is thought to result from overproduction of pro-angiogenic growth factors, including vascular epithelial growth factor (VEGF). 4, 5 However, targeted inhibition of VEGF alone using bevacizumab, a humanized monoclonal antibody for VEGF-A, has shown only limited efficacy. [6] [7] [8] [9] [10] Preclinical data suggest that overexpression of hepatocyte growth factor receptor (MET) in GBM may aid in eventual resistance to bevacizumab, 11, 12 suggesting that targeted inhibition of both MET and VEGF may overcome these challenges. Further, studies in a variety of tumor types have suggested that chronic inhibition of VEGF results in upregulation of both MET and AXL, 13, 14 and inhibition of AXL during anti-VEGF therapy also increases efficacy through prolonging resistance. 15, 16 Further, both MET 12, [17] [18] [19] and AXL [20] [21] [22] [23] have been implicated in GBM pathogenesis and are associated with poor prognosis in patients with GBM. Thus, inhibition of MET, AXL, and VEGF may have a significant impact on outcomes in patients with recurrent GBM.
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) with activity against VEGF receptors, MET, and AXL. 24, 25 Preclinical data have shown suppression of MET and VEGF receptor 2 (VEGFR2) signaling with improved survival in a mouse xenograft model, 26 and clinical trials in solid tumors have demonstrated tumor regression. [27] [28] [29] A recent open-label, phase II trial in patients with recurrent GBM has shown some evidence of clinical activity 30, 31 ; however, radiographic response evaluation in patients receiving anti-VEGF therapy can be particularly challenging due to the dramatic changes in contrast enhancement from decreased vascular permeability regardless of antitumor activity. [32] [33] [34] [35] [36] [37] Previous studies have shown that digital subtraction of pre-from postcontrast T1-weighted images, or "T1 subtraction maps, " improves visualization and volumetric quantification of subtly enhancing tumor. Additionally, early changes in contrast-enhancing tumor volume defined using T1 subtraction maps have been shown to predict long-term clinical outcome in recurrent GBM treated with bevacizumab. 38 Therefore, in the current study we examine whether early radiographic response defined using quantitative tumor volume estimates from T1 subtraction maps could predict overall survival (OS) in an open-label, phase II, multicenter clinical trial of bevacizumab-naïve recurrent GBM patients treated with cabozantinib (NCT00704288).
Methods

Patients
Included in the current retrospective study were 152 patients who had not previously failed anti-angiogenic therapy (ie, bevacizumab, cediranib, or pazopanib) of the 222 total patients enrolled in XL184-201, a multicenter (8 sites) , phase II, open-label, uncontrolled study of cabozantinib, a TKI with principal targets of MET, VEGFR2, AXL, and RET, at doses of 140 or 100 mg (free base equivalent weight, oral, daily) in patients with recurrent GBM at first or second relapse. Of these patients, a total of 108 (N = 87 for 100 mg and N = 21 for 140 mg) had serial MR images (at least 3 to confirm response) with sufficient quality available for volumetric analyses. The median age for these patients was 56.5 years (range = 21-73) and, of the patients included, approximately 65% were male. All patients included had Karnofsky performance status of more than 70 at baseline. The study spanned from June 2008 through July 2014. In all patients, initial standard radiation therapy and chemotherapy (concurrent radiation therapy and temozolomide treatment) failed, and radiation therapy (or previous investigational drugs) had been completed more than 12 weeks previously. Baseline images were obtained within 14 days prior to treatment according to study guidelines, and follow-up imaging was performed every 6 to 8 weeks until disease progression. The current imaging analysis was performed retrospectively using data from the study sponsor (Exelixis). All participants in XL184-201 signed institutional review board-approved informed consent at their respective institutions prior to enrolling in the multicenter clinical trial. Specific inclusion and exclusion criteria for this trial can be found at clinicaltrials.gov/ct2/ show/NCT00704288.
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Magnetic Resonance Imaging
Anatomic MR images were acquired for all patients in the current study using a 1.5T or 3T clinical MR scanner using pulse sequences supplied by their respective manufacturers and according to their local standard-of-care protocols. Standard anatomic images consisted of precontrast, 2D axial T1-weighted fast spin-echo (repetition time (msec)/echo time (msec) = 400-3209/3.6-21.9; slice thickness = 3-6.5 mm; intersection gap = 0-2.5 mm; number of averages = 1-2; matrix size = 176-512 × 256-512; and field of view = 24-25.6 cm) along with T2-weighted fast spin-echo and fluid-attenuated inversion-recovery (FLAIR) images. In addition, parameter matched axial 2D T1-weighted fast spin-echo images enhanced with gadopentetate dimeglumine (Magnevist, Berlex), 0.1 mmol/ kg, were acquired shortly after contrast material injection, followed by MPRAGE (3D magnetization-prepared rapid acquisition gradient-echo) sequences in most patients.
Contrast-Enhanced T1-Weighted Digital Subtraction Maps
Contrast-enhanced T1-weighted subtraction maps ( Fig. 1 ) were created using parameter matched pre-and postcontrast axial 2D T1-weighted images and techniques previously described. 38 First, linear registration was performed between all images, including contrast-enhanced T1-weighted images and T2-weighted and/or FLAIR images to non-enhanced T1-weighted images using a 12 degree-of-freedom transformation and a correlation coefficient cost function in FSL (FLIRT; FMRIB Software Library, Oxford, England; http://www.fmrib.ox.ac.uk/fsl/). Next, "Gaussian normalization" of image intensity for both non-enhanced and contrast-enhanced T1-weighted images was performed using custom c-code and bash Note that in both cases, as in many patients exhibiting a durable response, we observed significant T1 shortening on precontrast T1-weighted images following therapy, which resulted in a significant decrease in true contrast-enhancing tumor burden following digital subtraction. 
Results
T1 subtraction maps provided clear benefit for delineating contrast-enhancing tumor from surrounding tissue in patients treated with cabozantinib. Fig. 1 illustrates representative images from 2 patients with recurrent GBM who experienced a sustained volumetric response using T1 subtraction maps after treatment with cabozantinib at a dose of 100 mg. In both of these cases, as with many patients who experienced volumetric response, a significant level of T1 shortening (hyperintensity) was observed on precontrast T1-weighted images following initial treatment (Fig. 1B, D) . After T1 subtraction it was apparent that most of the observed residual contrast enhancement on postcontrast T1-weighted images following therapy was likely attributed to precontrast T1 shortening, resulting in a relatively small volume of posttreatment contrast enhancement tumor burden. Approximately 38.9% of patients (42 of 108) with recurrent GBM treated with cabozantinib at either dose experienced a durable volumetric radiographic response, as defined by a sustained decrease on enhancing volume greater than 65% for at least 4 weeks ( Table 1 ). In patients treated with 100 mg of cabozantinib (N = 87) and patients treated with 140 mg of cabozantinib (N = 21), 41 .4% (36 of 87) and 28.6% (6 of 21), respectively, experienced a confirmed volumetric response.
As reported previously, baseline enhancing tumor volume is an independent and significant prognostic factor for OS in patients treated with cabozantinib. 42 A reexamination of this previous data suggests that a simple loglinear model can be used to predict OS given only the volume of contrast-enhancing tumor prior to treatment ( Fig. 2A ; OS = −4.7•log 10 (Volume) + 31.7 mo; P = 0.0006). Examination of the initial change in contrast-enhancing tumor volume following administration of cabozantinib N = number of subjects in the specified population. (Fig. 2B ) suggests a linear relationship between the degree of tumor shrinkage and OS benefit (OS = −0.04•(Change in Volume) + 10.6 mo; P = 0.0256).
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Univariate log-rank analysis suggested a significant survival advantage in patients exhibiting a confirmed volumetric response (median OS = 20.6 mo) compared with patients who did not respond (median OS = 8.0 mo) when pooling patients from both dose levels ( Fig. 3A; hazard ratio [HR] = 0.3050, P < 0.0001). When splitting patients by dose, significant survival differences still remained between volumetric responders and nonresponders (Fig. 3B) . In particular, patients treated with either 100 mg or 140 mg of cabozantinib who exhibited a sustained volumetric response had a significantly longer OS (HR = 0.3842 and HR = 0.1132, respectively; P < 0.0001). Additionally, patients who responded to 140 mg had a significantly longer OS compared with responders treated with 100 mg (HR = 0.3448, P = 0.0211), suggesting there may be dose-dependent survival benefit for patients with recurrent GBM treated with cabozantinib. Multivariable Cox regression showed that continuous baseline tumor volume (HR = 1.0233, P < 0.0001) and confirmed volumetric response (HR = 0.2240, P < 0.0001) were independent predictors of OS, while age (HR = 1.0038, P = 0.7022) and dose level (HR = 0.9885, P = 0.1368) were not statistically significant independent predictors when accounting for these other covariates (Table 2 ).
Discussion
The current study indicates that T1 subtraction maps provide equivalent (eg, Fig. 1A, C) or improved (eg, Fig. 1B, D) visualization and detailed demarcation for quantitation of enhancing disease burden in GBM. Results from the current trial provide additional support for the use of T1 subtraction maps to estimate change in contrast-enhancing tumor volume as an early surrogate of treatment efficacy in recurrent GBM based on initial response, similar to those reported previously after treatment with bevacizumab. 38 A recent study by Gahrmann et al 43 examining bevacizumab therapy in the BELOB trial suggests that T1 subtraction maps provided only equivalent performance for identifying time to progression compared with postcontrast T1-weighted images alone. This suggests that the largest added value of T1 subtraction in recurrent GBM may be in assessment of early response, rather than early disease progression, in anti-angiogenic therapies. Importantly, the current study indicates that patients with a large and sustained reduction in contrast-enhancing tumor volume following cabozantinib therapy will experience more than twice the survival benefit compared with patients who do not. This large and clinically meaningful difference in OS implies that early changes in contrast-enhancing tumor volume using T1 subtraction may be a robust imaging biomarker for OS benefit in recurrent GBM.
The rates of confirmed volumetric response (38.9% overall, 41.1% for 100 mg, and 28.6% for 140 mg) in the current study (N = 108) were substantially higher than the objective response rates reported for this same trial (N = 152) by an independent radiological facility using criteria from Response Assessment in Neuro-Oncology (RANO) (14.5% and 17.6% for 100 mg and 140 mg doses, respectively 30 ). These rates were similar to response rates reported for bevacizumab using traditional postcontrast T1-weighted images and modified Macdonald or RANO criteria 6, 44, 45 (28%-63%), yet higher than traditional chemotherapies like irinotecan. 46, 47 Interestingly, patients treated with cabozantinib who had long posttreatment OS had notable T1 shortening on precontrast T1-weighted images. This was in notable contrast to patients with long posttreatment OS following bevacizumab, in which significant T1 hypointensity was observed. Subsequent studies aimed at determining the source of post-cabozantinib T1 shortening in recurrent GBM may be warranted to determine whether it has biologic or prognostic significance.
Despite occurring less frequently, a volumetric response in patients treated with 140 mg appeared to impart a longer OS compared with 100 mg. Although speculative given the small sample size, this may suggest increased therapeutic efficacy with increased dose, so long as tumor shrinkage is observed early after the start of therapy. Additional studies at higher doses may be warranted provided they are safe and tolerated, 30 as the 140 mg/day dose has been approved for treatment of medullary thyroid cancer based on results from the pivotal phase III trials. 27, 48 The current study had a few limitations that should be addressed. First, this study was retrospective and as such the conclusions were solely based on the data available for advanced image analyses wherein only 108 of the 152 patients treated in the trial had sufficient imaging for analysis. 31 Additionally, lesion segmentation was not fully automated or controlled and involved multiple layers of human interpretation. Thus, some variability in lesion size measurement and response rate may have been present and unaccounted for. Lastly, the current study does not involve a formal comparison to the traditional RANO criteria, so questions still remain regarding the added value of the current technique with respect to other, more accepted approaches commonly used in clinical trials.
In conclusion, results from the current study suggest that volumetric analysis using T1 subtraction maps represents a detailed and informative assessment method to evaluate response of GBM patients treated with anti-angiogenic therapy. Results support the hypothesis that volumetric response predicts OS in patients treated with cabozantinib and suggests that cabozantinib may have clinical activity in more than one third of recurrent anti-angiogenic therapy naïve GBM patients as evidenced by a durable volumetric response using T1 subtraction maps associated with a significant survival benefit. 
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